Condition: Unresectable Hepatocellular Carcinoma (HCC) · Sponsor: Bangladesh Medical University
The goal of this interventional study is to compare treatment response between transarterial chemoembolization (TACE) combined with lenvatinib and lenvatinib monotherapy in patients with unresectable hepatocellular carcinoma. The study aims to determine whether the addition of TACE to lenvatinib results in improved tumor response compared with lenvatinib alone in a real-world clinical setting.
This description comes directly from the study's public registry record.
Sourav Kumar Chakraborty · +8801747473455 · drsouravhepato@gmail.com
Md. Ayub Al Mamun, FCPS (Medicine) · +8801725876589 · ayubmamunal@gmail.com
Always discuss trial participation with your own doctor first.
| Department of Hepatology, Bangladesh Medical University | Dhaka, Bangladesh | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07408804